PE20130524A1 - Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis - Google Patents
Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosisInfo
- Publication number
- PE20130524A1 PE20130524A1 PE2012001815A PE2012001815A PE20130524A1 PE 20130524 A1 PE20130524 A1 PE 20130524A1 PE 2012001815 A PE2012001815 A PE 2012001815A PE 2012001815 A PE2012001815 A PE 2012001815A PE 20130524 A1 PE20130524 A1 PE 20130524A1
- Authority
- PE
- Peru
- Prior art keywords
- endometrosis
- gestagen
- treatment
- pharmaceutical form
- aromatase
- Prior art date
Links
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 2
- 102000014654 Aromatase Human genes 0.000 title 1
- 108010078554 Aromatase Proteins 0.000 title 1
- 239000003418 antiprogestin Substances 0.000 title 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 abstract 3
- 229960002932 anastrozole Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 abstract 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 abstract 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- -1 PENTROZOLE Chemical compound 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- 229960000255 exemestane Drugs 0.000 abstract 1
- 229960004421 formestane Drugs 0.000 abstract 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 abstract 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 abstract 1
- 229960003881 letrozole Drugs 0.000 abstract 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 1
- 229960004400 levonorgestrel Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 229960001771 vorozole Drugs 0.000 abstract 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010003494A DE102010003494A1 (de) | 2010-03-31 | 2010-03-31 | Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130524A1 true PE20130524A1 (es) | 2013-04-26 |
Family
ID=44021822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012001815A PE20130524A1 (es) | 2010-03-31 | 2011-03-28 | Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis |
Country Status (41)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
| JP2018515796A (ja) * | 2015-05-27 | 2018-06-14 | クエスト ダイアグノスティックス インヴェストメンツ エルエルシー | マイクロサンプリングデバイスにより抽出された被分析物の質量分析による定量のための方法 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| RU2732822C2 (ru) * | 2015-12-21 | 2020-09-22 | Байер Ой | Способ изготовления устройства доставки лекарственного средства и устройство доставки лекарственного средства, изготовленное указанным способом |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
| GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
| CN109248166A (zh) * | 2017-07-13 | 2019-01-22 | 国家卫生计生委科学技术研究所 | 阿那曲唑储库型阴道环的制备及应用 |
| US10918649B2 (en) | 2019-06-21 | 2021-02-16 | The Population Council, Inc. | System for providing birth control |
| WO2022174074A1 (en) * | 2021-02-12 | 2022-08-18 | The Regents Of The University Of California | Endometriosis-related methods and compositions |
| WO2023163914A1 (en) * | 2022-02-22 | 2023-08-31 | Celanese Eva Performance Polymers Llc | Intravaginal ring device for the delivery of aromatase inhibitor |
| CN115804762B (zh) * | 2022-12-20 | 2024-05-31 | 浙江大学 | 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8517360D0 (en) * | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
| JP2602456B2 (ja) * | 1990-04-12 | 1997-04-23 | 雪印乳業株式会社 | 子宮内膜症治療剤 |
| FI95768C (fi) * | 1993-06-17 | 1996-03-25 | Leiras Oy | Emättimensisäinen antosysteemi |
| US7744916B2 (en) * | 1997-06-11 | 2010-06-29 | Umd, Inc. | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs |
| FI20000572A7 (fi) * | 2000-03-13 | 2001-09-14 | Schering Oy | Implantaattien asettamiseen tarkoitettu laite |
| JP2004519490A (ja) * | 2001-01-26 | 2004-07-02 | フアルマシア・イタリア・エツセ・ピー・アー | エキセメスタンによるホルモン依存性異常症の組合せ治療方法 |
| GB0120147D0 (en) * | 2001-08-17 | 2001-10-10 | Metris Therapeutics Ltd | Treatment method |
| WO2003017974A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method |
| GB0302572D0 (en) * | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
| GB0320238D0 (en) * | 2003-08-29 | 2003-10-01 | Medical Res Council | Treatment of disease |
| US20050101579A1 (en) * | 2003-11-06 | 2005-05-12 | Shippen Eugene R. | Endometriosis treatment protocol |
| AR066166A1 (es) * | 2007-09-21 | 2009-07-29 | Organon Nv | Sistema de suministro de droga |
| TW200927141A (en) * | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
| US20110033519A1 (en) * | 2009-08-07 | 2011-02-10 | Leong Madeline | Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use |
-
2010
- 2010-03-31 DE DE102010003494A patent/DE102010003494A1/de not_active Withdrawn
-
2011
- 2011-03-28 DK DK11714245.5T patent/DK2552404T3/en active
- 2011-03-28 WO PCT/EP2011/054737 patent/WO2011120925A1/de not_active Ceased
- 2011-03-28 PT PT11714245T patent/PT2552404E/pt unknown
- 2011-03-28 US US13/638,243 patent/US20130131027A1/en not_active Abandoned
- 2011-03-28 RS RS20150188A patent/RS53876B1/sr unknown
- 2011-03-28 ME MEP-2015-39A patent/ME02159B/me unknown
- 2011-03-28 CN CN201180017806.6A patent/CN103002873B/zh not_active Expired - Fee Related
- 2011-03-28 CA CA2794790A patent/CA2794790A1/en not_active Abandoned
- 2011-03-28 BR BR112012024739A patent/BR112012024739A2/pt not_active IP Right Cessation
- 2011-03-28 EP EP11714245.5A patent/EP2552404B1/de active Active
- 2011-03-28 MA MA35266A patent/MA34099B1/fr unknown
- 2011-03-28 KR KR1020127025671A patent/KR20130010047A/ko not_active Ceased
- 2011-03-28 MX MX2012011329A patent/MX2012011329A/es active IP Right Grant
- 2011-03-28 EA EA201201358A patent/EA025582B1/ru not_active IP Right Cessation
- 2011-03-28 SI SI201130435T patent/SI2552404T1/sl unknown
- 2011-03-28 JP JP2013501792A patent/JP6012048B2/ja not_active Expired - Fee Related
- 2011-03-28 PH PH1/2012/501944A patent/PH12012501944A1/en unknown
- 2011-03-28 PE PE2012001815A patent/PE20130524A1/es not_active Application Discontinuation
- 2011-03-28 NZ NZ602698A patent/NZ602698A/en not_active IP Right Cessation
- 2011-03-28 PL PL11714245T patent/PL2552404T3/pl unknown
- 2011-03-28 HR HRP20150294TT patent/HRP20150294T1/hr unknown
- 2011-03-28 ES ES11714245.5T patent/ES2533101T3/es active Active
- 2011-03-28 SG SG2012068847A patent/SG184111A1/en unknown
- 2011-03-28 AU AU2011234587A patent/AU2011234587B2/en not_active Ceased
- 2011-03-28 MY MYPI2012004360A patent/MY160353A/en unknown
- 2011-03-28 UA UAA201212231A patent/UA109655C2/uk unknown
- 2011-03-30 UY UY0001033303A patent/UY33303A/es not_active Application Discontinuation
- 2011-03-30 TW TW105118443A patent/TW201632184A/zh unknown
- 2011-03-30 AR ARP110101037A patent/AR080861A1/es unknown
- 2011-03-30 TW TW100111100A patent/TWI576107B/zh not_active IP Right Cessation
-
2012
- 2012-09-13 ZA ZA2012/06869A patent/ZA201206869B/en unknown
- 2012-09-23 IL IL222056A patent/IL222056A/en not_active IP Right Cessation
- 2012-09-24 EC ECSP12012176 patent/ECSP12012176A/es unknown
- 2012-09-27 TN TNP2012000468A patent/TN2012000468A1/en unknown
- 2012-09-27 CR CR20120493A patent/CR20120493A/es unknown
- 2012-09-28 CO CO12170798A patent/CO6630125A2/es unknown
- 2012-09-28 CL CL2012002722A patent/CL2012002722A1/es unknown
- 2012-09-28 GT GT201200267A patent/GT201200267A/es unknown
- 2012-09-28 DO DO2012000255A patent/DOP2012000255A/es unknown
- 2012-09-28 CU CU2012000145A patent/CU20120145A7/es unknown
-
2015
- 2015-03-17 CY CY20151100269T patent/CY1116187T1/el unknown
- 2015-06-18 US US14/743,935 patent/US20150359802A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115248A patent/JP2016164200A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130524A1 (es) | Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis | |
| AR080912A1 (es) | Formas de dosificacion solidas orales con dosis muy bajas para la hrt | |
| AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
| EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
| BR112012020731A2 (pt) | pastilhas gelatinosas suaves com nicotina. | |
| CR7611A (es) | Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona | |
| AR085934A1 (es) | Tratamiento de mieloma multiple con masitinib | |
| ZA202202320B (en) | Oral pharmaceutical composition containing heterocyclic compound | |
| PE20060275A1 (es) | Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual | |
| CR9627A (es) | Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof | |
| SV2011003896A (es) | Pirrolidinas | |
| CO2019002616A2 (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos | |
| CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
| RU2009127776A (ru) | Профилактическое или терапевтическое средство от алопеции | |
| CL2008000931A1 (es) | Particula solidad de vacuna oral entrecruzada que contiene un ingrediente farmaceuticamente activo un bioadhesivo, un oligasacarido, una mezcla mediadiora que comprende un emulsionante y uno o mas monosacaridos y/o disacaridos; metodo para su preparacion; uso de la particula solidad de vacuna oral. | |
| AR066232A1 (es) | Combinacion de antagonista del receptor de progesterona con un inhibidor de la aromatasa para usar en enfermedades mediadas por brca (genes supresores de tumores) | |
| NI201400066A (es) | Anillo vaginal que comprende meloxicam y un agente modulador de la libración del principio activo, útil como anticonceptivo de uso continuo en mujeres | |
| UA67100U (ru) | Способ лечения переднего эндогенного увеита | |
| TR201714149A2 (tr) | Ulipristal asetat içeren bir tablet formülasyonu. | |
| UY30530A1 (es) | Forma farmacologica peroral para la anticoncepcion | |
| MX2023012801A (es) | Nueva formulacion. | |
| TH104140A (th) | อนุพันธ์ 17-ไฮดรอกซี-19-นอร์-21-คาร์บอกซิลิคแอซิด-สเตอรอยด์ แกมมา-แลคโตน การใช้สารนี้และผลิตภัณฑ์ทางยาที่มีอนุพันธ์นี้อยู่ด้วย | |
| CO7151514A2 (es) | Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia. | |
| RU2007141999A (ru) | Лекарственное средство | |
| CL2012000499A1 (es) | Forma de dosificación farmacéutica sólida oral de liberación extendida que comprende una formulación matricial de liberación extendida que comprende 5 a 500 mg de clorhidrato de oxicodona y al menos 80 % (p/p) de oxido de polietileno (pm 1.000.000); y su uso para tratar el dolor (div. sol. n° 200702485). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |